JAMA Oncology
@jamaoncology.com
JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.
🌐 JAMAOncology.com
🌐 JAMAOncology.com
On December 1 at 10 AM ET, JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new @who.int guideline concerning #GLP-1 therapy and adults with #obesity.
Register for the webinar: ja.ma/43V8C1I
Register for the webinar: ja.ma/43V8C1I
November 28, 2025 at 6:36 PM
On December 1 at 10 AM ET, JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new @who.int guideline concerning #GLP-1 therapy and adults with #obesity.
Register for the webinar: ja.ma/43V8C1I
Register for the webinar: ja.ma/43V8C1I
Among adolescents and young adults with #cancer, 9.5% of patients with earlier-stage cancer experienced metastatic recurrence within five years, with the highest rates in sarcoma (24.5%) and colorectal cancer (21.8%).
ja.ma/4rnNKdt
ja.ma/4rnNKdt
November 28, 2025 at 3:00 PM
Among adolescents and young adults with #cancer, 9.5% of patients with earlier-stage cancer experienced metastatic recurrence within five years, with the highest rates in sarcoma (24.5%) and colorectal cancer (21.8%).
ja.ma/4rnNKdt
ja.ma/4rnNKdt
In early 2025, the National Cancer Institute terminated 181 extramural grants, totaling more than $640 million in awards. Terminations targeted primarily basic science, general oncology, and early-career investigators.
ja.ma/3LTwhto
ja.ma/3LTwhto
November 28, 2025 at 3:00 PM
In early 2025, the National Cancer Institute terminated 181 extramural grants, totaling more than $640 million in awards. Terminations targeted primarily basic science, general oncology, and early-career investigators.
ja.ma/3LTwhto
ja.ma/3LTwhto
With an estimated 1.8 million deaths annually, primary lung cancer is the leading cause of cancer-related deaths.
This Review discusses the controversies and challenges in the treatment of synchronous oligometastatic NSCLC without an AGA.
ja.ma/4obHPFz
This Review discusses the controversies and challenges in the treatment of synchronous oligometastatic NSCLC without an AGA.
ja.ma/4obHPFz
November 28, 2025 at 12:00 PM
With an estimated 1.8 million deaths annually, primary lung cancer is the leading cause of cancer-related deaths.
This Review discusses the controversies and challenges in the treatment of synchronous oligometastatic NSCLC without an AGA.
ja.ma/4obHPFz
This Review discusses the controversies and challenges in the treatment of synchronous oligometastatic NSCLC without an AGA.
ja.ma/4obHPFz
Phase 2 trial finds lorlatinib yielded a 73% objective response rate and median progression-free survival of 53.6 months in TKI-naive advanced ROS1-positive NSCLC.
ja.ma/3XeWTrb
ja.ma/3XeWTrb
November 27, 2025 at 3:00 PM
Phase 2 trial finds lorlatinib yielded a 73% objective response rate and median progression-free survival of 53.6 months in TKI-naive advanced ROS1-positive NSCLC.
ja.ma/3XeWTrb
ja.ma/3XeWTrb
Patient-reported outcomes, such as higher health status and lower symptom burden, are independently associated with improved overall survival in cancer patients. ja.ma/4rrb22o
November 27, 2025 at 12:00 PM
Patient-reported outcomes, such as higher health status and lower symptom burden, are independently associated with improved overall survival in cancer patients. ja.ma/4rrb22o
Metastatic recurrence continues to be a leading cause of morbidity and mortality among patients with solid tumors.
Listen to authors Ann Brunson, MS, and Theresa Keegan, PhD, MS, discuss this and more with JAMA Oncology Web Editor, Vivek Subbiah, MD: ja.ma/49H6RJd
Listen to authors Ann Brunson, MS, and Theresa Keegan, PhD, MS, discuss this and more with JAMA Oncology Web Editor, Vivek Subbiah, MD: ja.ma/49H6RJd
November 26, 2025 at 5:30 PM
Metastatic recurrence continues to be a leading cause of morbidity and mortality among patients with solid tumors.
Listen to authors Ann Brunson, MS, and Theresa Keegan, PhD, MS, discuss this and more with JAMA Oncology Web Editor, Vivek Subbiah, MD: ja.ma/49H6RJd
Listen to authors Ann Brunson, MS, and Theresa Keegan, PhD, MS, discuss this and more with JAMA Oncology Web Editor, Vivek Subbiah, MD: ja.ma/49H6RJd
💬 Editorial: Metastatic recurrence nearly triples mortality risk in #BreastCancer among young adults and increases death risk in sarcoma and colorectal cancer—highlighting the need for earlier detection and novel treatments.
ja.ma/43QeKbz
ja.ma/43QeKbz
November 26, 2025 at 5:00 PM
💬 Editorial: Metastatic recurrence nearly triples mortality risk in #BreastCancer among young adults and increases death risk in sarcoma and colorectal cancer—highlighting the need for earlier detection and novel treatments.
ja.ma/43QeKbz
ja.ma/43QeKbz
On December 1 at 10 AM ET, JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #GLP-1 therapy and adults with #obesity.
Register for the webinar: ja.ma/4of3Zqx
Register for the webinar: ja.ma/4of3Zqx
November 26, 2025 at 5:00 PM
On December 1 at 10 AM ET, JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #GLP-1 therapy and adults with #obesity.
Register for the webinar: ja.ma/4of3Zqx
Register for the webinar: ja.ma/4of3Zqx
Among adolescents and young adults with #cancer, 9.5% of patients with earlier-stage cancer experienced metastatic recurrence within five years, with the highest rates in sarcoma (24.5%) and colorectal cancer (21.8%).
ja.ma/49Al4Yq
ja.ma/49Al4Yq
November 26, 2025 at 4:30 PM
Among adolescents and young adults with #cancer, 9.5% of patients with earlier-stage cancer experienced metastatic recurrence within five years, with the highest rates in sarcoma (24.5%) and colorectal cancer (21.8%).
ja.ma/49Al4Yq
ja.ma/49Al4Yq
Proton craniospinal irradiation significantly improves survival outcomes compared to involved-field radiotherapy for patients with leptomeningeal metastases from non–small cell lung cancer and breast cancer.
ja.ma/4puO9sK
ja.ma/4puO9sK
November 26, 2025 at 12:00 PM
Proton craniospinal irradiation significantly improves survival outcomes compared to involved-field radiotherapy for patients with leptomeningeal metastases from non–small cell lung cancer and breast cancer.
ja.ma/4puO9sK
ja.ma/4puO9sK
Head and neck cancer is the seventh most common cancer worldwide.
This Review provides an overview of EGFR-targeted therapies in HNSCC.
ja.ma/48gSBEN
This Review provides an overview of EGFR-targeted therapies in HNSCC.
ja.ma/48gSBEN
November 25, 2025 at 5:55 PM
Head and neck cancer is the seventh most common cancer worldwide.
This Review provides an overview of EGFR-targeted therapies in HNSCC.
ja.ma/48gSBEN
This Review provides an overview of EGFR-targeted therapies in HNSCC.
ja.ma/48gSBEN
Editorial: Comparative efficacy between 400-mg and 600-mg ribociclib doses in hormone receptor–positive breast cancer is clinically minimal, but differences in toxicity are significant. ja.ma/4if5uDH
November 24, 2025 at 12:30 PM
Editorial: Comparative efficacy between 400-mg and 600-mg ribociclib doses in hormone receptor–positive breast cancer is clinically minimal, but differences in toxicity are significant. ja.ma/4if5uDH
Four-year NATALEE trial results show ribociclib plus NSAI maintains invasive disease-free survival benefit over NSAI alone in hormone receptor–positive/ERBB2-negative early breast cancer. ja.ma/4obDpOU
November 24, 2025 at 12:00 PM
Four-year NATALEE trial results show ribociclib plus NSAI maintains invasive disease-free survival benefit over NSAI alone in hormone receptor–positive/ERBB2-negative early breast cancer. ja.ma/4obDpOU
💬 Viewpoint: The badscopal effect following ablative radiotherapy signals not failure but biological reorganization, prompting serial metastasis-directed therapy in selected patients.
ja.ma/3LYQX2X
ja.ma/3LYQX2X
November 23, 2025 at 3:00 PM
💬 Viewpoint: The badscopal effect following ablative radiotherapy signals not failure but biological reorganization, prompting serial metastasis-directed therapy in selected patients.
ja.ma/3LYQX2X
ja.ma/3LYQX2X
💬 Viewpoint: The badscopal effect following ablative radiotherapy signals not failure but biological reorganization, prompting serial metastasis-directed therapy in selected patients.
ja.ma/48d4qvu
ja.ma/48d4qvu
November 23, 2025 at 1:00 PM
💬 Viewpoint: The badscopal effect following ablative radiotherapy signals not failure but biological reorganization, prompting serial metastasis-directed therapy in selected patients.
ja.ma/48d4qvu
ja.ma/48d4qvu
For adults with metastatic HER2-positive #BiliaryTractCancer, zanidatamab led to longer overall survival and reduced pain, supporting its role as a precision therapy option. ja.ma/4oewULf
November 22, 2025 at 3:00 PM
For adults with metastatic HER2-positive #BiliaryTractCancer, zanidatamab led to longer overall survival and reduced pain, supporting its role as a precision therapy option. ja.ma/4oewULf
For adults with metastatic HER2-positive #BiliaryTractCancer, zanidatamab led to longer overall survival and reduced pain, supporting its role as a precision therapy option. ja.ma/48pnesN
November 22, 2025 at 3:00 PM
For adults with metastatic HER2-positive #BiliaryTractCancer, zanidatamab led to longer overall survival and reduced pain, supporting its role as a precision therapy option. ja.ma/48pnesN
The IMPACT tool accurately stratifies incidental meningioma patients by progression risk, supporting early intervention for high-risk, monitoring for medium-risk, and safe discharge for low-risk individuals. ja.ma/49xigv4
November 21, 2025 at 3:00 PM
The IMPACT tool accurately stratifies incidental meningioma patients by progression risk, supporting early intervention for high-risk, monitoring for medium-risk, and safe discharge for low-risk individuals. ja.ma/49xigv4
In active surveillance for #ProstateCancer, #MRI was most reliable for ruling out significant cancer in low PSA density cases but failed to achieve sufficient accuracy in broader populations. ja.ma/4oTrhDF
November 20, 2025 at 5:00 PM
In active surveillance for #ProstateCancer, #MRI was most reliable for ruling out significant cancer in low PSA density cases but failed to achieve sufficient accuracy in broader populations. ja.ma/4oTrhDF
Meta-analysis: Among patients with intermediate-, high-, or very high-risk prostate cancer, the ideal duration of ADT with radiotherapy demonstrated nonlinear benefits, with diminished gains after 12 months and variation in benefit by risk group. ja.ma/4rf4JPi
November 20, 2025 at 4:30 PM
Meta-analysis: Among patients with intermediate-, high-, or very high-risk prostate cancer, the ideal duration of ADT with radiotherapy demonstrated nonlinear benefits, with diminished gains after 12 months and variation in benefit by risk group. ja.ma/4rf4JPi
💬 Viewpoint: #Medicaid cuts and work requirements in the 2025 budget law risk reduced access to cancer prevention, delayed diagnoses, later-stage disease at presentation, and caused worse cancer outcomes. ja.ma/47EGnGV
November 16, 2025 at 2:00 PM
💬 Viewpoint: #Medicaid cuts and work requirements in the 2025 budget law risk reduced access to cancer prevention, delayed diagnoses, later-stage disease at presentation, and caused worse cancer outcomes. ja.ma/47EGnGV
💬 Viewpoint: Trust in medicine has declined due to the #COVID19 pandemic and abundant online health information, highlighting the need for transparent, patient-focused communication. ja.ma/49Qp9aQ
November 16, 2025 at 12:00 PM
💬 Viewpoint: Trust in medicine has declined due to the #COVID19 pandemic and abundant online health information, highlighting the need for transparent, patient-focused communication. ja.ma/49Qp9aQ
Among patients with advanced urothelial cancer, upfront enfortumab vedotin dose reduction was linked to a 50% reduction in treatment interruption risk but did not compromise overall survival. ja.ma/3K384QB
November 15, 2025 at 2:00 PM
Among patients with advanced urothelial cancer, upfront enfortumab vedotin dose reduction was linked to a 50% reduction in treatment interruption risk but did not compromise overall survival. ja.ma/3K384QB
💬 Viewpoint: #OvarianCancer's unique attributes complicate early detection, necessitating personalized risk-based strategies for better prevention and outcomes. ja.ma/4hVdIAO
November 15, 2025 at 12:00 PM
💬 Viewpoint: #OvarianCancer's unique attributes complicate early detection, necessitating personalized risk-based strategies for better prevention and outcomes. ja.ma/4hVdIAO